Related Experiment Video
Updated: Jul 6, 2026

Traditional Trail Making Test Modified into Brand-new Assessment Tools: Digital and Walking Trail Making Test
Published on: November 23, 2019
Mcl-1: a gateway to TRAIL sensitization
Seok-Hyun Kim1, M Stacey Ricci, Wafik S El-Deiry
1Laboratory of Molecular Oncology and Cell Cycle Regulation, Department of Medicine, Institute for Translational Medicine and Therapeutics, Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Abstract:
The proapoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is being evaluated presently as a selective anticancer agent, but its limited effects against cancer cell lines has raised some concerns about its ultimate clinical utility. Here, we review recent findings that cancer cell sensitivity to TRAIL is greatly increased when the Bcl-2 family protein Mcl-1 is down-regulated by the Raf/vascular endothelial growth factor kinase inhibitor sorafenib, a Food and Drug Administration-approved cancer drug. Using the TRAIL-sorafenib combination as a tactic to more effectively kill cancer cells may provide an effective tool to attack a variety of human cancers that are largely presently untreatable.
Insights
Combining tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) with sorafenib enhances cancer cell killing. This combination therapy, by down-regulating Mcl-1, offers a promising strategy against difficult-to-treat cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- The proapoptotic cytokine tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) shows potential as a selective anticancer agent.
- Limited efficacy of TRAIL against certain cancer cell lines raises concerns about its clinical utility.
Purpose of the Study:
- To review findings on enhancing cancer cell sensitivity to TRAIL.
- To explore the role of Mcl-1 down-regulation in TRAIL-mediated apoptosis.
Main Methods:
- Review of recent scientific literature.
- Analysis of the effects of sorafenib on Mcl-1 expression.
- Investigation of combination therapy strategies.
Main Results:
- Sorafenib, a Raf/VEGF kinase inhibitor, significantly increases cancer cell sensitivity to TRAIL.
- Down-regulation of the Bcl-2 family protein Mcl-1 by sorafenib is a key mechanism.
- The combination of TRAIL and sorafenib demonstrates enhanced cancer cell killing.
Conclusions:
- The TRAIL-sorafenib combination therapy is a promising strategy for overcoming TRAIL resistance.
- This approach may offer an effective tool against various human cancers.
- Targeting Mcl-1 in conjunction with TRAIL could improve cancer treatment outcomes.
Related Concept Videos
Major Somatic Sensory Pathways
Overview of Somatic Sensory Pathways
The somatosensory system is divided into three main pathways: the dorsal (or posterior) column-medial lemniscus, spinothalamic (or anterolateral), and spinocerebellar pathways.
The dorsal...
Direct Motor Pathways
The corticospinal tract is responsible for the voluntary movement of the limbs and trunk. It originates in the cerebral cortex of the brain and descends through the cerebrum's internal capsule and the...
MAPK Signaling Cascades
Sympathetic Pathways: Sympathetic Chain Ganglia
Auditory Pathway
When viewed cross-sectionally, the cochlea reveals the scala vestibuli and scala tympani flanking the...

